Dr. Weidong Lu, MB, MPH, PhD
Dr. Weidong Lu is an Oncology Acupuncturist and the Oncology Acupuncture Team Leader at Dana-Farber Cancer Institute (DFCI). He is a principal investigator at the Dana-Farber/Harvard Cancer Center and the lead investigator of the Chinese Medicine Research Initiative at DFCI.
Dr. Lu is an Instructor in Medicine at Harvard Medical School and a Professor Emeritus of Chinese Medicine at the New England School of Acupuncture (NESA). He chairs the Committee on Acupuncture at the Massachusetts Board of Registration in Medicine.
Dr. Lu established the Oncology Acupuncture Specialty at DFCI in 2000 and has dedicated his research to integrative medicine, with a focus on integrative oncology. His research centers on developing the oncology acupuncture specialty; conducting clinical research on symptom management and supportive care using integrative approaches including acupuncture and Chinese herbal medicine; investigating drug-herbal interactions and their impacts on clinical practice; and designing and leading clinical trials of oncology acupuncture.
He has published over 60 peer-reviewed research papers and book chapters, and has presented his work nationally and globally, including North America, Europe, and Asia.